Celyad Completes 30-Day Safety Follow-Up In NKG2D CAR T-Cell Phase I Trial

(RTTNews) - Celyad SA (CYAD) Tuesday announced the completion of the 30-day safety follow-up of the final patient enrolled in the first cohort of the company's Phase I clinical trial, evaluating the safety and feasibility of its NKG2D CAR T-Cell therapy, in cancer patients suffering from acute myeloid leukemia or multiple myeloma.

This Phase I trial aims to assess the infusion of four escalating doses of NKG2D CAR T-Cells in four consecutive patients cohorts of three patients each.

Following infusion of the first dose of NKG2D CAR T-cells to the three patients of the first cohort, no treatment related safety issues were reported with the treatment over the follow-up period of 30 days.

Dr.Christian Homsy, CEO of Celyad, said,"These data mark an important step in demonstrating the safety of NKG2D CAR T-Cells infusion at single dose levels and allows us to initiate the enrolment of new patients for the second cohort of the trial.

"In order to boost enrolment of these new patients and also enable an extensive evaluation of this innovative approach, Celyad is extending the trial network to additional sites at renowned clinical sites in the U.S.," Homsy added.